Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CORR Insights®: How Is Lumbar Fusion Associated With Compensatory Hip Motion After THA?

Clinical orthopaedics and related research·2026
Same author

Exploring the Influence of Surgeon and Hospital Procedural Volume on the Outcomes of Distal Femoral Replacement: An Australian National Joint Replacement Registry Analysis.

ANZ journal of surgery·2025
Same author

Establishing the Frequency of the HLA Class II Pseudotumour 'at Risk' Genotype: A Pilot Epidemiologic Analysis.

ANZ journal of surgery·2025
Same author

Editorial: Advances in artificial intelligence and robotics in joint arthroplasty.

Arthroplasty (London, England)·2025
Same author

Early Patient-Reported Outcome Measures Following Computer Navigated Total Hip Arthroplasty: A Study From the Australian Orthopaedic Association National Joint Replacement Registry.

The Journal of arthroplasty·2024
Same author

Understanding immune-mediated titanium allergy to in situ orthopaedic implants: a narrative review of the current literature.

ANZ journal of surgery·2024

Related Experiment Video

Updated: Jun 13, 2026

Reverse Total Shoulder Arthroplasty
10:10

Reverse Total Shoulder Arthroplasty

Published on: July 5, 2011

Review article: thromboprophylaxis after total hip replacement.

Andrew P Kurmis1

  • 1Department of Orthopaedic Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia. andrew.kurmis@mh.org.au

Journal of Orthopaedic Surgery (Hong Kong)
|April 30, 2010
PubMed
Summary

Extended anticoagulant therapy after total hip replacement (THR) significantly reduces the risk of dangerous blood clots. Robust evidence supports longer thromboprophylaxis durations beyond 14 days for improved patient outcomes.

Related Experiment Videos

Last Updated: Jun 13, 2026

Reverse Total Shoulder Arthroplasty
10:10

Reverse Total Shoulder Arthroplasty

Published on: July 5, 2011

Area of Science:

  • Orthopedic Surgery
  • Hematology
  • Pharmacology

Background:

  • Total hip replacement (THR) surgery can induce a hypercoagulable state, increasing risks of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Current anticoagulant strategies aim to mitigate these risks, but optimal treatment duration remains debated.

Purpose of the Study:

  • To review the existing literature for evidence supporting extended thromboprophylaxis ( >14 days) after THR.
  • To assess the benefits and risks of prolonged anticoagulant therapy in this patient population.

Main Methods:

  • Comprehensive literature search of electronic databases (PubMed, EMBASE, CINAHL) and evidence libraries (Cochrane, BMJ Clinical Evidence).
  • Inclusion of English-language, full-text articles.
  • Meta-review of identified studies.

Main Results:

  • Robust evidence supports the routine use of extended thromboprophylaxis (>14 days) following THR.
  • Professional guidelines, including those from the American College of Chest Physicians, reflect this evidence.
  • Meta-review indicates a clear benefit, outweighing minor adverse event increases.

Conclusions:

  • Extended duration of thromboprophylaxis (>14 days) is recommended after total hip replacement.
  • Wider adoption of these extended regimens is supported by current evidence for improved patient safety.